Core Viewpoint - The company Bibeite (688759.SH) has initiated its subscription with an issue price of 17.78 yuan per share, focusing on innovative drug development in the biopharmaceutical sector, particularly targeting major diseases such as tumors and autoimmune diseases [1] Group 1: Company Overview - Bibeite is a biopharmaceutical company that emphasizes clinical value and is dedicated to the independent research and development of innovative drugs [1] - The company has one approved breakthrough therapy drug, BEBT-908, for the treatment of r/rDLBCL, and several other products in various stages of clinical trials [1] - BEBT-908 is the first-in-class small molecule dual-target inhibitor designed for HDAC/PI3Kα, with no other similar inhibitors approved or in development in China as of June 30, 2025 [1] Group 2: Financial Performance - For the fiscal years 2022, 2023, and 2024, the company's net profits are projected to be approximately -188 million yuan, -173 million yuan, and -55.998 million yuan respectively [2] - The company is currently not profitable and anticipates significant ongoing R&D investments, which will keep R&D expenses at a high level [2] - Due to the lack of profitability, the company may not be able to distribute profits or pay cash dividends in the short term [2]
A股申购 | 生物医药企业必贝特开启申购 5个产品处于I期临床试验阶段